English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Ibogaine Microdosing and Lithium Orotate: What to Actually Know
Somewhere between the flood-dose ibogaine treatment centers of Mexico and the quiet corners of online recovery forums, a smaller conversation has been building. It's about microdosing iboga — sometimes paired with a supplement called lithium orotate — as a slower, less dramatic way to work with this African root. Not the ceremony. Not the 36-hour visionary marathon. Just small, regular doses, taken with intention, over weeks or months. I've spent enough time around ibogaine, psychedelics, and the addiction-recovery world to know this topic gets messy fast. There's real signal here, and there's also a lot of wishful thinking. If you're considering microdosing iboga — or stacking it with lithium orotate — you deserve the honest version, not the Instagram version. So let's walk through it. Ibogaine is the primary psychoactive alkaloid in the root bark of Tabernanthe iboga, a shrub from West Central Africa where it's used ceremonially in the Bwiti tradition. In its full dose, it's known as one of the more physically demanding master plants — a long, introspective experience often used to interrupt opioid, alcohol, and stimulant addictions. Microdosing skips the ceremony entirely. Instead of one large session, people take sub-perceptual amounts — often somewhere between 20 and 300 milligrams of root bark, or a small fraction of that in isolated ibogaine HCl — on a schedule. The reported goals vary. Some people microdose to smooth out post-acute withdrawal after a full ibogaine treatment. Others use it for mood regulation, focus, mild depression, or to feel more grounded during long stretches of sobriety. A smaller group uses it for what they describe as ongoing soul exploration — a kind of steady, gentle contact with the plant rather than a single dramatic meeting. Here's the thing though: iboga is not psilocybin. It sits differently in the body. Even at small doses it can affect the heart, particularly QT interval, and it interacts with a long list of medications. Microdosing does not erase those cardiac considerations. It softens them, but it does not eliminate them. Anyone considering this should have a recent EKG and, ideally, bloodwork. Lithium orotate is not the prescription lithium carbonate used for bipolar disorder. It's a supplement sold over the counter in much of the U.S., dosed in the range of 1 to 20 milligrams of elemental lithium — a fraction of what a psychiatrist would prescribe. Advocates describe it as a mood stabilizer, anti-inflammatory, and neuroprotective agent. Skeptics point out that the human research on low-dose lithium is thin, mostly older, and often observational. Why does it come up in ibogaine microdosing circles? A few reasons. People coming off opioids or alcohol often deal with unstable moods, irritability, and sleep that refuses to cooperate. Low-dose lithium has a reputation — anecdotal, mostly — for taking the edge off that chaos. And in the small subculture that treats iboga microdosing as a long-term project, lithium orotate gets recommended as a kind of buffer: something that supports mood and neurons while the iboga does its slower work. Is there a clinical trial confirming this combination is safe or effective? No. There isn't. What exists is user reporting, a handful of forum threads, and the clinical intuition of a few harm-reduction practitioners. That's not nothing. But it's not a green light either. The short version: probably fine for most healthy adults at conservative doses, but there are real reasons to be careful and no reason to be cavalier. Ibogaine's headline safety concern is cardiac. It can prolong QT interval, which in rare cases triggers dangerous arrhythmias. Most reported deaths in the ibogaine literature involve either pre-existing heart conditions, hidden electrolyte imbalances, or dangerous drug interactions — particularly with methadone, other long-acting opioids, SSRIs, and stimulants. Microdoses carry a much smaller cardiac load, but people with a family history of heart issues, low potassium or magnesium, or eating disorders should think twice. Lithium at supplement doses is generally considered low-risk, but it's still a mineral your kidneys have to process. Anyone with kidney disease, thyroid problems, or a history of lithium sensitivity should talk to a doctor first. And if you're already on prescription psychiatric medication — SSRIs, benzos, mood stabilizers, antipsychotics — the picture gets complicated quickly. Iboga plus SSRIs is a documented bad combination. Adding lithium on top just adds variables. In my conversations with facilitators and integration coaches, the people drawn to iboga microdosing usually fall into three camps. First, post-treatment addicts — folks who did a full ibogaine flood at a clinic and are now in the fragile six-to-twelve-month window where relapse risk is highest. Microdosing, sometimes with lithium orotate, gets used as a scaffolding for that period. It's not a cure. It's a support beam. Second, people who never wanted a full ceremony but are curious about iboga's reputation for helping with stuck patterns — chronic low-grade depression, avoidance, the sense that nothing quite lands. These are often the readers who've already tried psilocybin microdosing and want something with different qualities. Iboga is more grounding, more physical, and, in my experience, less pleasant. It doesn't sparkle. It sits with you. Third, people using it for what I'd call maintenance — long-time meditators, therapists, folks in the psychedelic-assisted recovery world who treat small iboga doses as an ongoing dialogue with the plant. This is the smallest group and, honestly, the group I trust most, because they're rarely evangelizing. Most people who end up microdosing iboga responsibly got there after some kind of guided experience — a full ibogaine treatment, a provider consultation, or a structured retreat setting where they learned what the plant actually feels like in their body. Trying to build the whole practice yourself from scratch, using powder bought online, without ever meeting the plant properly, is how people get hurt. Or, more often, how they just get nothing out of it because they're dosing wrong. A good iboga or ibogaine retreat does a few things that are hard to replicate on your own. Medical screening. Cardiac monitoring. Facilitators who can tell whether what you're experiencing is normal or a warning sign. And, critically, an integration framework — the part where you figure out what to actually do with what came up. That last piece is usually what separates people who benefit long-term from people who have a big experience and then drift back to old patterns within a year. If you're weighing whether to book something, the questions worth asking a provider are boringly practical: What's your medical screening protocol? Who monitors participants during the experience? What's your position on microdosing afterward, and do you support integration for six months or just wave people off at the airport? The answers tell you almost everything. Ibogaine has been studied on and off since the 1960s, primarily for opioid dependence. The clinical picture is genuinely promising for addiction recovery — a 2024 Stanford study on ibogaine for traumatic brain injury and PTSD in veterans made headlines for good reason, and earlier observational work has consistently shown meaningful reductions in opioid withdrawal and craving. That's the substance's real claim to fame. Microdosing specifically? Almost no formal research. What we have is animal studies suggesting low-dose ibogaine and its metabolite noribogaine may support neuroplasticity and mood regulation, plus a growing pile of user reports. That's a legitimate hypothesis, not a proven therapy. Anyone selling you certainty here is either uninformed or selling something. Lithium orotate research is even thinner. Low-dose lithium in drinking water has been correlated with lower suicide rates in some population studies, and there's a small body of work suggesting neuroprotective effects. But dose-response, long-term safety in supplement form, and interactions with psychedelics are basically uncharted territory in the peer-reviewed literature. If you're seriously considering this path, slow down. Iboga rewards patience and punishes urgency. A reasonable sequence — and I want to be clear this is general orientation, not medical advice — usually looks something like this: Iboga is not a supplement you take for a boost. It's one of the more serious plant medicines humans have relationships with, and it takes those relationships seriously in return. The people I've watched benefit most from it are almost always the ones who approached it with a bit of dread, a lot of preparation, and no shortcuts. For readers who want to explore this in a supervised setting first, a range of ibogaine and iboga-focused retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — this plant tends to reward that.
Meditation Plateaus and Plant Medicine: When Sitting Practice Stops Working
Here's a scenario I keep hearing from people who eventually land at an ayahuasca retreat: they meditated. Not casually. Daily, for years. Twenty minutes some mornings, an hour on weekends, the occasional silent retreat where the food is bland and the schedule is brutal and they came home feeling like someone had wiped the fog off a windshield. And then, one day, the practice stopped working. Not dramatically. Nothing broke. They just noticed that the same cushion, the same breath, the same technique that used to open something in them had become — how to put it — routine. Maintenance. Brushing their teeth for the soul. That's the moment a certain kind of meditator starts googling ayahuasca, psilocybin, master plants, and whether any of it is legal where they live. If that's roughly where you are, this piece is for you. Meditation works. That's not the question. Decades of research and thousands of years of contemplative tradition agree that steady practice rewires how you relate to your own thoughts, your reactivity, your grief, your joy. What nobody prepares you for is the plateau — that stretch, often somewhere between year three and year seven, where the practice keeps giving you calm but stops giving you insight. Part of it is neurological. The brain is wildly adaptive. Whatever you do repeatedly, it gets efficient at, and efficient often means dulled. The same mindfulness technique that used to shake something loose in you eventually becomes a familiar loop your nervous system knows how to run without much friction. The edges get sanded down. That's actually the practice working as designed — but it can feel like stagnation. The other part is psychological. Sitting practice is exquisite at helping you observe patterns, but it's not always the sharpest tool for excavating them. Trauma buried in the body, addictive loops running in the background, grief you never fully let land — meditation can circle these for years without quite reaching in. Some people call this the spiritual bypass problem. You get very good at watching your suffering with equanimity and not so good at metabolizing it. Ayahuasca, psilocybin, San Pedro, ibogaine — the psychedelics and plant medicines that dominate the current wellness conversation — do something meditation generally doesn't. They pry the door open whether you're ready or not. Where a decade of vipassana might slowly loosen the grip of a repressed memory, a single ayahuasca ceremony can drag it into the room and put it on the floor in front of you. That's not necessarily a good thing. It's a different thing. And it's the reason experienced meditators are often the people who handle psychedelic experiences best — they already have a stable relationship with their own attention, they know how to breathe through discomfort, they don't panic when reality gets weird. The plant medicine world calls them, quietly, the good sitters. Here's what plant medicine tends to offer that a cushion practice does not: None of this replaces meditation. Ask any facilitator who's been at this longer than five minutes and they'll tell you the same thing: the plant does the opening, the practice does the integration. Without the second part, the first part is expensive tourism. Before you book a retreat in Peru, an honest question: are you stuck, or are you bored? These look identical from the inside and mean very different things. Stuck usually means a specific pattern — an addiction, a depression, a relationship dynamic, a grief — is not moving despite your best efforts, including meditation, therapy, and whatever else you've thrown at it. There's a felt sense of hitting the same wall from different angles. That's the kind of stuck plant medicine has a real chance of interrupting. Bored means your practice has become routine and you're hoping something dramatic will make you feel spiritually alive again. That's a fine motivation for a lot of things — a new hobby, travel, a different meditation lineage — but it's a shaky reason to drink ayahuasca. The medicine tends to punish thrill-seeking, sometimes literally, by delivering a night that has nothing to do with what you signed up for. A few honest questions to sit with: Real talk about what a well-run ayahuasca or psilocybin retreat looks like, because the internet is full of both breathless enthusiasm and paranoid warning. Neither is accurate. Most reputable retreats run somewhere between four and ten days. You'll do two to four ceremonies, spaced with rest days. There's a dieta beforehand — no alcohol, no pork, no recreational drugs, often no sex, sometimes no salt or sugar — for a period ranging from a few days to a few weeks depending on the tradition. You'll fill out a medical intake form that asks pointed questions about SSRIs, heart conditions, and family history of psychosis. A retreat that doesn't ask those questions is a retreat to avoid. The ceremonies themselves are usually held after dark, in a maloca or ceremonial space, with a facilitator or curandero singing icaros or holding silence. You'll probably purge. You might cry. You might see things that make no rational sense and feel more true than anything you've ever known. You might also have a boring night where mostly you notice how uncomfortable the mat is. All of these are normal. Cost varies wildly. A no-frills retreat in Peru might run $1,200 for a week. A luxury operation in Costa Rica with private rooms and gourmet food can hit $5,000 or more. Ibogaine treatment for addiction, which requires medical supervision, typically starts around $6,000 and climbs. Cheaper isn't always worse, and expensive isn't always safer — what matters is the facilitator's experience, the safety protocols, and the integration support. This is the part nobody who's selling you a retreat wants to dwell on. The ceremony is a doorway. Walking through it, sustainably, into a changed life — that's a project that unfolds over months and years. Meditators actually have an advantage here. You already have a daily contemplative practice. You already know how to sit with discomfort, notice thoughts, return to the body. After a plant medicine experience, that practice becomes the container that holds whatever came up. Without it, insights fade fast and old patterns reassert themselves within weeks. Good integration looks like: continued sitting practice, ideally slightly modified based on what you learned; a therapist who understands psychedelic experiences; time in nature; journaling; conversations with people who were in the ceremony with you; and, crucially, small behavioral changes you actually follow through on. The person who drinks ayahuasca, has a revelation about their drinking, and then goes back to their old bar the following Friday has learned nothing. The person who takes one small honest action every day for six months is the one whose life quietly rebuilds. The Amazonian traditions talk about master plants — ayahuasca, tobacco, chacruna, bobinsana, and others — as teachers. Not metaphorically. Literally. The idea is that certain plants have consciousness and personality and offer specific lessons to people who diet with them properly. You don't have to buy the cosmology to notice that the framing matters. It treats the medicine as a relationship, not a product. That reframe alone tends to make people take the experience more seriously than the recreational psychedelic culture usually does. For a meditator who's plateaued, the master plant framework might feel weirdly familiar. It's not so different from the guru relationship in some Buddhist and Hindu lineages — a teacher outside yourself who reflects something back that you couldn't see alone. Same function. Different form. None of this is a prescription. Plenty of long-term meditators go deeper into their practice, find a new lineage or teacher, or move into somatic and trauma-focused therapies and never touch a psychedelic. That's a legitimate path. Others find that a well-held ayahuasca or psilocybin experience cracks open something that years of sitting couldn't quite reach, and they go home with more work to do, not less. If that's the direction you're leaning, a range of thoughtfully vetted plant medicine and ayahuasca retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, if you end up meeting it, will still be there when you're actually ready.
Thinking About Trying LSD for the First Time? Read This First
So you've never taken LSD, and you're curious. Maybe a friend mentioned it changed how they saw their depression. Maybe you read a study about psilocybin and addiction and started falling down a rabbit hole. Maybe you're just tired — tired of the same loops in your head, the same patterns you can't seem to break. Whatever brought you here, welcome. Let's talk honestly. I've spent years covering psychedelics and plant medicine retreats — sitting in ayahuasca ceremonies, interviewing facilitators, listening to people describe their first mushroom trip at fifty-two after a lifetime of white-knuckling anxiety. What I've learned is this: the internet is full of hot takes on psychedelics, but very little of it is written for the person who's actually about to do this. That's you. So let's slow down. The stereotype is still stuck in 1968 — tie-dye, Grateful Dead, some guy named Rainbow handing out sugar cubes at a festival. That's not who's exploring psychedelics right now. The demographic has shifted, hard. The people I meet at retreats are software engineers who can't sleep, nurses processing pandemic burnout, veterans with PTSD, moms who lost a child, guys in their late twenties trying to quit drinking without another AA meeting. Most first-timers aren't chasing a party. They're chasing relief. And there's a growing body of research — from Johns Hopkins, Imperial College London, MAPS — suggesting that substances like psilocybin, MDMA, and ayahuasca may help with treatment-resistant depression, addiction, and trauma when used in the right container. Emphasis on right container. That phrase is doing a lot of work in that sentence. Here's something worth knowing before you go further. LSD is a synthetic compound. Ayahuasca, psilocybin mushrooms, San Pedro, iboga, peyote — these are what people in this world call master plants. They're not just chemistry. They come with lineage, ceremony, and a whole cosmology built around them by cultures that have used them for generations. Does that mean LSD is inferior? No. Plenty of people have had profound, life-reorganizing experiences on acid. But if you're looking at psychedelics because you want healing — not just novelty — the plant medicine path tends to come with more structure, more support, and more of a framework for making sense of what happens. Nobody can fully answer this for you, and anyone who claims to is either lying or hasn't done it. But some things are consistent enough across accounts to be worth naming. Time gets weird. You might feel like an hour has passed when it's been ten minutes. Or the opposite. Emotions come in waves — grief you didn't know you were carrying, joy that seems to arrive from nowhere, fear that feels ancient. Visuals happen, but they're rarely the point. Most people who come out of an ayahuasca ceremony or a high-dose mushroom session don't talk about the geometry. They talk about seeing their father clearly for the first time. Or realizing they've been angry at themselves for thirty years. It can also be uncomfortable. Sometimes very uncomfortable. Ayahuasca involves purging — vomiting, sometimes worse — and there's a reason people call it la purga. On mushrooms or LSD, difficult passages are common. This is not a failure. In psychedelic-assisted work, the hard parts are often where the medicine actually does its job. You just want someone experienced nearby when it happens. Here's the honest answer: no, you don't need a retreat to try psychedelics. People have had beautiful experiences with a trusted friend in a well-prepared living room. But retreats exist for a reason, and the reason is this — set and setting matter more than almost anything else, and most of us are terrible at engineering our own. A good retreat gives you: A bad retreat gives you none of those things and charges you three thousand dollars for the privilege. This is why choosing carefully matters so much. Read reviews from multiple sources. Ask about facilitator training. Ask what happens if someone has a medical or psychological emergency. If they get defensive, walk away. Short answer: the research is genuinely promising, and it's one of the most active areas of clinical study right now. Ibogaine has shown remarkable results with opioid addiction — some clinics report that a single treatment can interrupt withdrawal and cravings in ways nothing in Western medicine has matched. Ayahuasca has a long track record with alcohol dependency, particularly in the Amazonian traditions and increasingly in secular therapeutic settings. Psilocybin trials at Johns Hopkins showed strong outcomes for tobacco cessation. But — and this is important — psychedelics are not a magic delete button for addiction. What they seem to do is crack open a window. They give you a few hours where the compulsion loosens its grip and you can see your own patterns from the outside. What you do with that window is the rest of the work. Therapy, community, changed environments, honest self-inventory. The medicine is a catalyst, not a cure. The single biggest mistake first-timers make is arriving with a specific outcome in mind. "I want to heal my depression." "I want to understand my mother." "I want to stop drinking." These are reasonable intentions, but if you clutch them too tightly, the experience often gives you something completely different — and you'll spend the whole time frustrated instead of paying attention to what's actually being offered. The people I've watched get the most out of this work show up with something more like: "I'm open. Show me what I need to see." That's a very different posture. It's harder than it sounds. Physical safety with classical psychedelics — LSD, psilocybin, mescaline — is actually well-documented. They're not addictive in the pharmacological sense, and lethal overdoses are essentially unheard of at reasonable doses. The bigger risks are psychological. If you have a personal or family history of schizophrenia or bipolar disorder, most facilitators will (and should) turn you away. Certain SSRIs can blunt the experience or interact dangerously with substances like ayahuasca, which contains MAO inhibitors. The other risk is bad facilitation. There are real predators in this space — people who use altered states to manipulate participants, especially women. This is not a fringe concern; it's an ongoing problem in the underground scene and even at some legal retreats. Trust your gut during your research. If a facilitator's online presence feels culty, grandiose, or evasive about their training, believe that signal. LSD is Schedule I in the U.S. and illegal in most countries. Psilocybin is decriminalized in a handful of U.S. cities and legally available in therapeutic contexts in Oregon and Colorado as of the past couple of years. Ayahuasca is legal in Peru, Brazil, Costa Rica, and several other countries, which is why most reputable retreats operate abroad. Ibogaine is legal in Mexico and a handful of other places. This landscape shifts constantly — check current status before you book anything. Slow down. The rush to try psychedelics is often the same energy that got you stuck in the first place — the belief that the next thing will finally fix you. It might help. It might help a lot. But it works best when you approach it the way you'd approach any real surgery: with preparation, respect, and a plan for recovery. Read widely. Talk to people who've done it. Journal about why you're drawn to this. Get honest about what you're actually hoping for. And when you're ready to look at what a supported experience might look like, a curated selection of ayahuasca, psilocybin, and plant medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly.
First Psychedelic Trip: What Every Beginner Should Actually Know
So you're thinking about your first psychedelic experience. Maybe it's psilocybin mushrooms at a friend's cabin. Maybe it's a proper ayahuasca ceremony in Peru you've been eyeing for months. Maybe it's LSD at a music festival — which, for the record, I wouldn't recommend as a starting point, but people do it anyway. Whatever the substance, whatever the setting, the questions tend to be the same. What does it feel like? How much should I take? What if I panic? Is this actually going to help me, or am I about to have the worst night of my life for no good reason? Let's talk about it honestly. Not the Instagram version. Not the retreat brochure version. The version I wish someone had given me before my own first ceremony, when I was equal parts terrified and curious and pretending to be neither. Almost nobody takes psychedelics because they're bored. When I interview people at ayahuasca retreats — the ones who've flown from Toronto or Berlin or Melbourne to sit in a jungle maloca — they're usually there because something in ordinary life stopped working. Antidepressants that plateaued. Grief that wouldn't resolve. An addiction quietly running the show. A marriage in trouble. A career that looks fine on paper and feels like sandpaper. Master plants — that's what curanderos in the Amazon call ayahuasca, huachuma (San Pedro), and their relatives — have been used for what we'd now call addiction recovery, trauma work, and soul exploration for centuries. The Western clinical world is finally catching up. Serious research at Johns Hopkins, Imperial College London, and NYU has been looking at psilocybin for depression, treatment-resistant anxiety, and end-of-life distress. Ibogaine has a growing (and complicated) reputation for interrupting opioid dependence. This isn't fringe anymore. Still, none of that research means your first psychedelic experience is going to be therapeutic. It might be. It might also be strange, uncomfortable, boring in patches, or unexpectedly funny. Going in with the right expectations matters more than almost anything else. You'll hear these two words a lot. They're not marketing fluff. They're the closest thing psychedelic culture has to a safety protocol. Set is your mindset. What's going on in your head the week leading up, the day of, the hour before. Are you exhausted? Recently broken up? Fighting with your mother? Anxious about a work deadline? Whatever you bring in, the medicine will amplify. Psychedelics don't create emotional material out of nowhere — they turn the volume up on what's already there. Setting is where and with whom. A quiet room with someone sober and trustworthy present is a different universe from a crowded festival. A vetted retreat with experienced facilitators is a different universe from a stranger's living room. The setting shapes the experience more than most first-timers realize. Practical checklist before you sit with anything: The honest answer: it depends on the substance, the dose, and you. Psilocybin at a moderate dose tends to come on within 30 to 60 minutes. Colors get a little brighter. Music sounds thicker, more layered. Emotions arrive without a lot of warning — you might laugh until your face hurts, then cry about your grandfather for twenty minutes, then feel a strange calm you haven't felt in years. It usually lasts four to six hours. Ayahuasca is different — heavier, longer, more medicinal in feel. There's often a purge (vomiting, sometimes diarrhea, occasionally tears — the traditions consider all of it part of the cleanse). Visions can be intricate. Time distorts. Six hours can feel like an entire life. Some people meet what they describe as the plant itself, or ancestors, or aspects of themselves they'd forgotten. Others get a night of nothing much and are quietly furious about the airfare. Both outcomes are normal. LSD is longer still — eight to twelve hours — and tends to feel more mental than physical, more idea-driven than emotional, though it varies wildly by person. The one thing almost every first-timer underestimates is the afterward. The come-down, the next morning, the next week. Your baseline can feel oddly gentle. Small things you used to snap about seem less important. This window — sometimes called the integration period — is where the real work happens, if any is going to happen. Every experienced facilitator I've spoken with says the same thing: there are no bad trips, only difficult ones. That reframing sounds like a platitude until you're inside one. If fear arrives — and for a lot of first-timers, it does at some point — the instinct is to fight it. Don't. Fighting it is what turns discomfort into panic. The old advice still holds: The thing about difficult moments in ceremony is they're often the most useful part. What you resist tends to be the thing you needed to look at. That's not mysticism — it's how the brain works when its usual defenses are turned down. Physically, classic psychedelics (psilocybin, LSD, DMT, mescaline) are among the least toxic substances humans put into their bodies. You are not going to overdose on mushrooms in any medically meaningful sense. That's the good news. The complications are elsewhere. Ayahuasca contains MAOIs, which interact dangerously with SSRIs, some blood pressure medications, and various foods (aged cheese, cured meats, certain fermented things). If you're on antidepressants, you need to work with a knowledgeable doctor on a tapering plan long before ceremony. Ibogaine can affect the heart and requires medical screening — an ECG at minimum. People with a personal or strong family history of schizophrenia or bipolar disorder should generally avoid classic psychedelics; the risk of destabilization is real. Then there's the psychological safety of the setting itself. The plant-medicine world has genuine masters and also plenty of grifters, tourists in shaman's clothing, and outright predators. Vetting matters. Talk to former participants — not the ones on the retreat's website, the ones you find yourself. Ask about safety protocols, medical screening, what happens if someone has a hard time, and how women in particular are looked after (this last question separates serious operators from sketchy ones quickly). For a genuine first experience with a serious substance, a well-run retreat is almost always the better call. You get medical screening, experienced facilitators, a container designed for the state you're about to enter, and integration support after. You also get taken out of your daily environment, which matters more than it sounds. Home experiences aren't inherently worse — plenty of people have had profound psilocybin sessions in their own living rooms with a trusted sitter. But they require you to be your own facilitator, and first-timers rarely know what they don't know. If you're leaning toward a formal setting, spend real time comparing options. Lineage of the facilitators, size of the groups, medical support on site, integration offerings, and reviews from actual attendees all matter more than the beauty of the location. For readers ready to look at specific options, curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here — starting there tends to be less overwhelming than the open internet. Whatever you choose, take it seriously. This isn't a party. It's not a vacation, exactly. Done well, it's one of the more consequential things a person can do with a weekend of their life. Done badly, it's an expensive way to be scared for six hours. The difference is almost entirely preparation.
Psilocybin vs. LSD: Which Psychedelic Is Right for Your Healing Journey?
The question comes up in almost every conversation I have with people considering their first serious psychedelic experience: mushrooms or LSD? It sounds like a matter of taste, like picking red wine over white. It isn't. These two substances behave differently in the body, feel different in the mind, and tend to serve different kinds of inner work. Choosing between them — or deciding they're both worth exploring — is a real decision, and it deserves more than a Reddit shrug. I've sat with both. I've watched close friends have life-shifting experiences with psilocybin and equally profound ones with LSD. I've also seen people pick the wrong molecule for their situation and spend eight hours wishing they'd chosen differently. So let's walk through what actually separates these two, why it matters for anyone considering a psychedelic retreat or ceremony, and how to think about which one might suit you. Psilocybin is the psychoactive compound in what most people call magic mushrooms — dozens of species in the Psilocybe genus, growing on every inhabited continent. Humans have been eating them ceremonially for thousands of years. The Mazatec people of Oaxaca were using them in healing rituals long before Western scientists ever heard the word. Psilocybin converts to psilocin in your body, binds to serotonin receptors, and shows you something. What it shows you tends to feel old. Earthy. Bodied. LSD is a laboratory child. Albert Hofmann synthesized it in 1938 from ergot fungus, discovered its psychoactive punch by accident five years later, and gave the twentieth century a new tool for exploring consciousness. It's a semi-synthetic molecule active at doses measured in micrograms — extraordinarily potent by weight. It also hits serotonin receptors, but with a different affinity profile, and the experience it produces reflects that. Cleaner, in a sense. More electric. More architectural. Both are classic serotonergic psychedelics. Both can produce ego dissolution, mystical experiences, and lasting shifts in perspective. But the texture of the two journeys is genuinely distinct, and that texture matters more than most first-timers realize. A moderate psilocybin dose — say, 2 to 3.5 grams of dried Psilocybe cubensis — usually comes on within 30 to 60 minutes. There's often a wave of nausea in the first hour. Your body might feel heavy, or trembly, or both. Colors deepen. Patterns emerge in wood grain, in fabric, in the veins of leaves. And then, somewhere in hour two, the thing you came for arrives. People often describe mushrooms as feeling alive — as if there's an intelligence in the experience meeting them halfway. This is why psilocybin sits so comfortably alongside ayahuasca and other master plants in the plant medicine world. It has a personality. It can be tender. It can also be blunt in ways that leave you laughing and crying at the same time. Emotional material tends to come up in waves, often connected to specific memories, relationships, or unresolved grief. The whole experience typically runs four to six hours, with a gentle taper. The comedown is usually kind. Many people sleep well the night of a mushroom journey and wake up quiet, reflective, sometimes changed in ways they can't yet articulate. That afterglow is one reason psilocybin has become the darling of clinical research into depression, end-of-life anxiety, and addiction recovery. LSD is a longer trip — 8 to 12 hours is normal, and the last stretch can drag if you're tired. The come-up is subtler than mushrooms and less physical. You don't get that gut-level nausea. Instead you get a slow-building buzz, a sharpening of the visual field, a sense that your mind is speeding up while the world is holding still. The character of an LSD experience skews cerebral. Ideas cascade. Connections between disparate concepts feel obvious and important. Visuals are often geometric — fractals, breathing walls, tracers, the shimmer of pattern behind ordinary surfaces. Emotionally, LSD can be intense, but it's rarely as tender as psilocybin. It's more likely to hand you a philosophical breakthrough than a good cry. That's a generalization, of course. Set and setting shape everything. LSD also has more of a stimulant edge. Your jaw might clench. Sleep won't come easily even after the trip ends. Some people love this quality — the sustained clarity, the long runway for exploring an idea or a landscape. Others find it exhausting, especially in the final hours when the visuals fade but the wakefulness lingers. Here's where the choice really matters. If your interest in psychedelics is therapeutic — if you're circling this question because of depression, anxiety, addiction, trauma, or a stuck life pattern — psilocybin is usually the more suitable starting point. There are a few reasons. LSD has its place. Some people, especially those wrestling with rigid thinking, creative blocks, or entrenched worldviews, find that LSD's cognitive flexibility is exactly the medicine they need. It's also easier to microdose consistently because the material is stable and precisely dosable. But for the kind of deep, felt-sense healing that draws most people to plant medicine, mushrooms tend to be the better tool. Most people don't actually get to choose the molecule at a retreat — they choose the retreat, and the medicine comes with it. Ayahuasca retreats offer ayahuasca. Psilocybin retreats offer psilocybin. LSD retreats are much rarer, partly because of legal risk and partly because the long duration doesn't lend itself to a traditional ceremonial format. So the real practical question is: what kind of experience are you drawn to? If you want the earthy, embodied, plant-medicine texture — ayahuasca or psilocybin. If you want something more cerebral and less rooted in indigenous tradition, LSD is harder to find in a supported retreat setting but does exist in some European contexts. Ask yourself: Your honest answers point somewhere. A skilled facilitator can help you sort the rest. Both substances are classic psychedelics with excellent physiological safety profiles at recreational and ceremonial doses. Neither is addictive in the pharmacological sense. Neither has a known lethal dose in humans through direct toxicity. That said, they are not without risk. People with personal or family histories of schizophrenia, bipolar I, or psychotic disorders should generally avoid both. SSRIs blunt the effects and can complicate the experience. Certain heart conditions raise the stakes. And the psychological risk — a genuinely difficult trip that leaves you shaken for weeks — is real for anyone, especially without proper support. This is the argument for doing this work in a container with experienced people rather than solo in your apartment on a Tuesday. Legally, psilocybin is decriminalized or legally accessible in a growing number of jurisdictions — Oregon and Colorado in the U.S., the Netherlands for truffles, Jamaica for mushrooms outright. LSD remains a controlled substance in nearly every country. This is another reason you'll find far more psilocybin retreats than LSD ones. If someone asked me which I'd recommend for a first serious psychedelic experience with healing intentions, I'd say mushrooms, in a proper setting, with people who know what they're doing. If they asked me which I'd recommend for a curious mind wanting to expand its philosophical horizons on a long free Saturday with a trusted friend, I might say LSD. Neither answer is universal. Both are honest. The deeper truth is that the molecule matters less than the container. A well-held psilocybin ceremony with skilled facilitators will do more for you than a chaotic LSD session with acquaintances, and vice versa. Preparation, intention, setting, and integration shape the outcome as much as the substance itself. If you're drawn to explore psilocybin in a supported ceremonial setting, a curated range of psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. This is worth doing well.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Ibogaine Aftermath: Sleep Paralysis, Weird Nights, and What's Actually Normal
A few weeks after an ibogaine flood, you're back home. The heavy visionary part is behind you. You expect to feel lighter — and often you do. Then one night you wake up at 3 a.m., aware but frozen, and something in the room feels off. Welcome to one of the least-discussed corners of ibogaine recovery: the strange post-flood sleep. Sleep paralysis episodes, vivid dreams that feel more real than real, sudden wake-ups at odd hours — these show up in the ibogaine trip reports people share with each other but rarely in the marketing copy of retreats. If you're researching ibogaine for addiction or trauma, you deserve the honest picture. So let's talk about what actually happens after the ceremony ends. Sleep paralysis is a normal biological glitch. Your brain wakes up before your body does. During REM sleep, your muscles are switched off so you don't act out dreams — sometimes that switch takes an extra minute to flip back on when you rouse. You're conscious. You can't move. Sometimes you sense a presence in the room. Sometimes you see or hear things that aren't there. None of that is unique to ibogaine. Roughly a quarter of people experience it at some point in their lives, usually after a stretch of poor sleep or a shifted schedule. What ibogaine seems to do, in some people, is crank up the frequency of these episodes for a while — sometimes for days, sometimes for a couple of months post-flood. The reports tend to share a few features. You wake in the middle of the night. You can feel your body but can't move it. The atmosphere in the room feels charged, like the ceremony wasn't quite finished. Some people describe hearing the iboga song or seeing geometric patterns on the ceiling. Others describe a heavy, almost archetypal figure at the edge of the bed. It usually lasts under a minute, though inside the experience it feels much longer. Ibogaine has a genuinely long tail. Its main metabolite, noribogaine, sticks around in body tissues for weeks — some studies suggest measurable levels for a month or more after a single dose. That's part of what makes it interesting for addiction recovery: the brain keeps re-organizing long after the acute experience is over. It's also part of why sleep gets weird. Here's what seems to be going on, based on what facilitators, researchers, and participants describe: Add all of that together and you get a brain that's rearranging itself while trying to sleep. Some nights it works fine. Other nights you get the frozen-body, wide-awake, something's-in-the-room experience. Short answer: usually part of the process. Longer answer: it depends on what else is going on with you. Most people who report sleep paralysis after an ibogaine flood also report that it fades over a few weeks. It tends to cluster in the first month, get sporadic in the second, and mostly disappear after that. The people who seem to have the roughest time with it are the ones who go home to chaotic environments, skip integration, or try to power through with alcohol and stimulants right away. Warning signs that suggest you should talk to a doctor or a facilitator who knows ibogaine, not just wait it out: For a lot of people the sleep weirdness is unsettling but not harmful. It's the nervous system doing housekeeping in the background. That doesn't mean you have to like it. There's no magic fix, but participants and facilitators tend to converge on a similar set of practices. None of these are dramatic — they're the boring fundamentals that actually matter more than any supplement stack. One more thing worth mentioning: if you had a facilitator or clinic guide you through the flood, they should still be available in the weeks after. A retreat that hands you a ceremony and then goes silent is, honestly, doing a bad job. Reputable ibogaine programs check in during the aftercare window because they know the tail is where a lot of the real work happens. Ibogaine sits in a strange corner of the psychedelic landscape. It's one of the few plant medicines with genuine, replicated evidence for interrupting opioid dependence — people walk out of a flood without the acute withdrawal that would otherwise take weeks. That's remarkable. It's also a serious medicine with real cardiac risks, a long metabolite half-life, and the kind of post-experience terrain we've been talking about. Compared to ayahuasca or psilocybin retreats, ibogaine tends to be more medically supervised, more expensive, and shorter — usually a single flood dose followed by rest days and integration. The visionary content is often described as auto-biographical and stern, less about cosmic dissolution and more about being shown, in unsparing detail, the shape of your own life. People who come to it for addiction recovery often describe the aftermath as the harder part: the door is open, but you still have to walk through it, and your sleep might be weird while you do. If you're weighing whether ibogaine is right for you, the sleep paralysis question is a good proxy for a bigger question — are you set up for the tail, not just the ceremony? Do you have a quiet place to land? Someone to talk to? A schedule that lets you rest when your body needs to? Are you working with a clinic that will still take your call in week six? Those factors will shape your outcome more than the specific medicine on the day. For readers who want to explore this path further, curated ibogaine and plant-medicine retreats with integration support can be browsed on our marketplace here. Whatever you decide, go in with your eyes open — and give yourself the runway to land properly on the other side.
Psychedelic Therapy Approvals: What Practitioners and Patients Should Watch For
Something strange is happening in psychiatry. The word psychedelic, which spent half a century as a slur in medical circles, is now sitting inside FDA guidance documents, billion-dollar acquisition press releases, and Veterans Affairs training programs. If you are researching an ayahuasca retreat or considering psilocybin for depression, this matters — because the framework being built right now will shape who gets to sit with you, what it costs, and how safe the whole enterprise actually is. This is a snapshot of where preparedness stands as regulators, clinicians, and pharma companies inch toward what could be the first approved psychedelic therapeutics in the United States. It's messy. It's political. And the people in the room disagree about almost everything — which, honestly, is a healthy sign. Preparedness sounds like a bureaucratic term. It isn't. When someone in the field says preparedness, they mean two overlapping things: are there enough trained people to sit with patients during a psychedelic session, and are there enough systems — clinics, protocols, insurance codes, referral pathways — to make the whole thing work outside a research trial. Right now, honestly, the answer to both is no. The catch is that approvals may arrive before the workforce and the systems do. Psychedelic-assisted therapy isn't like handing someone a prescription for an SSRI. A session can run six to eight hours. Someone qualified has to be present the entire time. Preparation and integration sessions bracket the dosing day. Multiply that by the number of Americans with treatment-resistant depression or PTSD and you can see the labor problem. Which brings us to the people who might actually be doing this work. Who are they? Where are they being trained? And what happens when the training pipeline doesn't match the demand? Last month, the FDA published its final guidance on the clinical investigation of psychedelic drugs. That document had been in draft form since 2023, and its finalization is a real milestone — not because it dictates how you'll experience a legal psilocybin session someday, but because it sets the terms for the trials that determine whether approval happens at all. A few things worth knowing if you're a curious reader trying to follow the news: Two things to hold in mind. First, this guidance is about clinical trials, not about how eventual legal therapy will be delivered day-to-day in a clinic. Those rules come later. Second, some researchers feel the FDA is holding psychedelics to a stricter standard than other psychiatric drugs. Others think that scrutiny is warranted given how novel these treatments are. Both camps make defensible arguments. Eli Lilly, one of the largest pharmaceutical companies on earth, announced it's acquiring AtaiBeckley for up to $3.8 billion. The prize is BPL-003, an intranasal 5-MeO-DMT formulation being developed for treatment-resistant depression. It's the biggest psychedelic deal to date, following on the heels of Otsuka acquiring the methylone developer Transcend and AbbVie picking up Gilgamesh's lead candidate late last year. Something to notice: Lilly's press release didn't use the word psychedelic once. The framing was “rapid reductions in depressive symptoms.” No mention of the experience itself. That framing — the substance as a fast-acting antidepressant with an inconvenient side effect of, you know, a mystical experience — is where a lot of the philosophical fights in this field are happening. Here's the awkward part. 5-MeO-DMT is famously intense. Anyone who has spent time around bufo ceremonies knows the reports: brief, overwhelming, occasionally destabilizing. Some people describe it as the most catalytic experience of their lives. Others describe months of difficult integration afterward. Whether that molecule fits neatly into a Spravato-style clinic model, where patients might be in and out within a couple of hours, is a live question. Practitioners are asking it. Investors, largely, are not. Definium Therapeutics released positive Phase 3 results for its LSD candidate DT120 in major depressive disorder. A single 100-microgram dose in an orally disintegrating tablet, compared against placebo, produced an 8.1-point separation on the standard depression scale at six weeks. That's a strong signal by psychiatric drug standards. The trial enrolled participants whose current depressive episode had lasted around nine months on average — many had already tried multiple antidepressants without success. This isn't the same population as some of the psilocybin trials, which have focused on treatment-resistant depression with much longer episode durations, so head-to-head comparisons come with caveats. Still, it's the first Phase 3 LSD readout of the modern era, and it landed on the positive side. For a reader deciding whether to pursue a psychedelic retreat right now, none of these approvals will help you this year. But the direction of travel is worth understanding. Legal, insurance-covered psychedelic therapy is closer than most people realize — and further away than the headlines suggest. Here's where the medical model conversation collides with the reality that thousands of people already travel for ceremonies each year. Ayahuasca retreats in Peru, psilocybin retreats in Jamaica and the Netherlands, ibogaine centers in Mexico — this whole ecosystem exists because people didn't want to wait for the FDA. And in many cases, because their condition wasn't going to be helped by another SSRI trial anyway. If you're weighing a retreat this year or next, the regulatory news changes surprisingly little about your decision-making. What you still need to evaluate is the same short list of things retreat-seekers have always had to evaluate: The eventual arrival of licensed clinical psychedelic therapy won't make retreats disappear. The two settings serve different needs and different people. Someone with severe treatment-resistant depression may benefit enormously from a structured clinical trial. Someone processing spiritual crisis, grief, or long-buried trauma may find more of what they need in a ceremonial container. Neither setting is automatically safer, and neither is automatically more effective. What matters, more than the label on the door, is the competence and integrity of the people inside it. A few threads worth tracking if you follow this space: The honest read is that this is a slow revolution dressed up as a fast one. Approvals will come, probably, but the workforce won't materialize overnight, and the debates over how to train, credential, and pay these practitioners are only beginning. For readers who want to explore the ceremonial side of this world while the clinical side finishes building itself, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever path you end up on, take the decision seriously — the people sitting with you matter more than any headline about approvals, acquisitions, or trial results.
LSD for Anxiety: What the New Phase 3 Trial Results Actually Mean
Something quietly significant happened in psychedelic drug development this summer. A pharmaceutical version of LSD hit its primary endpoint in a Phase 3 trial for generalized anxiety disorder — the largest, most rigorous stage of clinical testing before a drug can be considered for approval. For anyone who's been watching the slow, halting return of psychedelics to mainstream psychiatry, that's not a small footnote. It's a real inflection point. And yet most of the coverage has been buried in industry newsletters and biotech press releases. So let's translate. What did the trial actually show? What does it mean for someone considering a psychedelic experience for their own anxiety or depression? And — the question nobody in a lab coat wants to answer directly — how does any of this relate to what people are already doing at ayahuasca retreats and psilocybin ceremonies around the world? The developer, a clinical-stage company focused on LSD-based therapeutics, reported that its Phase 3 study of a pharmaceutical LSD candidate met its primary endpoint in patients with generalized anxiety disorder (GAD). It also hit key secondary endpoints — meaning the drug didn't just squeak across the line on the main measure of anxiety reduction, but showed consistent effects across additional benchmarks the trial was designed to test. Phase 3 matters because it's the point where a treatment is tested at scale, against placebo, under the kind of regulatory scrutiny that determines whether it can be prescribed. Earlier phases prove safety and hint at effectiveness. Phase 3 is where a lot of promising drugs quietly fall apart. This one didn't. The GAD result also came only about two months after the same company reported positive Phase 3 data for LSD in major depressive disorder. Two Phase 3 wins in a single summer, on two of the most common and stubborn conditions in psychiatry, is the kind of run that changes how boardrooms and regulators talk about psychedelic medicine. Here's the thing about GAD: it's everywhere, and current treatments are mediocre. SSRIs help some people. Benzodiazepines work in the short term and create their own problems in the long term. Cognitive behavioral therapy is genuinely useful but slow, and many people simply don't have access to a good therapist. Meanwhile, the number of adults living with chronic, low-grade dread — the kind that hums under every meeting, every commute, every attempt to fall asleep — keeps climbing. Anxiety is also notoriously hard to treat with psychedelics in a research context. Depression trials have dominated the headlines because depressed patients often respond dramatically to a single dosing session. Anxiety is trickier. Some patients find that classic psychedelics can amplify fear before they ease it, which is why set, setting, and preparation matter so much. Running a controlled trial that actually reduces anxiety, on average, across dozens of patients — without the trial itself becoming a scary experience — is a real design challenge. That the study cleared its endpoints suggests the protocol handled that challenge reasonably well. It doesn't mean everyone in the trial had a smooth ride. It means the group, on balance, ended up meaningfully less anxious than the placebo group. Topline results are exactly that — the top of a much larger dataset that will be picked apart at conferences and in peer review over the next year. A few things worth keeping in mind before anyone declares LSD the new gold standard for anxiety: None of this is a knock on the results. It's just the honest frame for reading them. This is where a lot of readers get confused, and reasonably so. The company running these trials is developing what will eventually be a prescribed medication — a specific dose, a specific formulation, delivered under medical supervision inside a licensed clinic or hospital. It's LSD, chemically, but the entire delivery system around it is medical. Compare that to the reality of the broader psychedelic and plant medicine world. Right now, most people seeking psychedelic experiences for depression, anxiety, addiction, or stuck life patterns aren't waiting for the FDA. They're traveling to Peru, Costa Rica, Mexico, the Netherlands, or Jamaica to sit with ayahuasca, psilocybin, San Pedro, or ibogaine in ceremonial or retreat settings. The intention overlaps. The framework doesn't. Neither approach is universally better. They're answering slightly different questions: Different questions, different tools, different risks. Someone with severe GAD who has failed multiple medications may eventually benefit enormously from a licensed LSD protocol, if and when it becomes available. Someone whose anxiety is tangled up with grief, spiritual crisis, or a decade of unprocessed experience might find more of what they need in a well-run ayahuasca retreat with proper integration support. Some people, honestly, want both — a ceremony to break something open, and a therapist to help them make sense of it. Every successful Phase 3 readout does two things at once. It brings a specific drug closer to approval, and it changes the temperature of the whole field. Regulators, insurers, and clinicians start taking the category more seriously. Investors either pile in or pull back based on how the results are interpreted. And — this is the part most people miss — the cultural conversation shifts. When LSD, MDMA, or psilocybin move from “illegal drug of concern” to “Phase 3 clinical asset,” the taboo around discussing them cracks a little wider. Family doctors are more willing to talk about them. Employers offering mental health benefits start asking questions. People who wouldn't have considered a psychedelic experience five years ago begin to wonder, quietly, whether it might help them. That shift is why interest in ayahuasca retreats and psilocybin retreats has been climbing steadily even as clinical trials have moved slowly. The two worlds feed each other. The research legitimizes the conversation. The lived experiences — often gathered at retreats, described by returning participants — keep the human dimension in view. You probably didn't land here for a biotech update. You're likely somewhere in the process of asking whether a psychedelic retreat is right for you — for anxiety, depression, addiction, or something harder to name. The trial results above are useful context, but they don't answer your question. Let me try to answer it more directly. A few things to think about before you book anything: The research world is validating what many people have already been finding on the ground — that these compounds, held properly, can help with conditions where standard treatments have plateaued. The clinical version will arrive when it arrives. In the meantime, retreat-based options continue to be how most people encounter this work, and for the right person, in the right setting, they can be genuinely transformative. If any of this is prompting you to look further, a wide range of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — the best retreat is rarely the first one you find, and the questions you ask beforehand tend to matter more than the ceremony itself.
Stopping ADHD Medication Before an Iboga Ceremony: A Practical Timeline
If you take Adderall, Vyvanse, Ritalin, or another ADHD stimulant and you're considering an iboga ceremony, the first serious question you'll run into isn't whether iboga works. It's a much more practical one: how far in advance do I need to come off my medication? And the honest answer — the one you probably won't get in a five-minute intake call — is more nuanced than most retreat websites let on. This matters because iboga is not psilocybin. It's not ayahuasca. Ibogaine and its sister alkaloids act on the heart in a specific, measurable way, and stacking a stimulant on top of that is the fastest route to a genuinely dangerous ceremony. So let's talk about what the timeline actually looks like, what facilitators are checking for, and how to think about the taper without wrecking your life in the weeks beforehand. Ibogaine — the primary active alkaloid in the iboga root — prolongs something called the QT interval on your heart's electrical cycle. In plain English, it makes each heartbeat take slightly longer to reset. On its own, in a healthy person, that's manageable and one of the reasons reputable clinics require an EKG before dosing. Stack a stimulant on top, though, and the risk profile shifts fast. Stimulants like amphetamines and methylphenidate work in roughly the opposite direction of what iboga wants: they raise heart rate, elevate blood pressure, and keep the sympathetic nervous system on high alert. Iboga, particularly at flood-dose levels, needs your cardiovascular system to be as calm and predictable as possible. Adding a stimulant is a bit like flooring the accelerator while someone else is trying to service the engine. Beyond the heart, there's the neurochemistry. Iboga works on dopamine, serotonin, and the opioid system in a broad, resetting sort of way. If you've been pushing dopamine receptors with a daily stimulant for years, your baseline is not where iboga expects to find it. That doesn't necessarily mean the medicine won't work — but it does mean the experience can feel muddier, more physically taxing, and harder to integrate. There isn't a single universal number, and any facilitator who gives you one without asking follow-up questions is a small red flag. That said, here's the range you'll hear most often from experienced iboga providers: Some clinics push these windows further out. A cautious ibogaine clinic in Mexico or Costa Rica may want you clean of amphetamines for a full three weeks, especially if you've been on a high daily dose for years. Others, dealing with less concentrated iboga preparations in ceremonial settings, may be comfortable with shorter windows. The variance is real, and it's why you need to have this conversation with your specific facilitator — not with a Reddit thread or with me. Retreats that do this well ask you to fill out a detailed medical intake, request a recent EKG, and sometimes ask for bloodwork including a magnesium and potassium panel. If your facilitator hasn't asked about your ADHD medication by name, dose, and duration of use, that's information you need to volunteer — and it's fair to wonder what else they're not screening for. When you have the conversation, be specific. Tell them: A good facilitator will use that information to give you a taper plan, not just a stop date. Cold-turkey stopping a stimulant you've been on for a decade the week before a ceremony is a rough plan for a rough ceremony. Better to taper down over a few weeks and hit ceremony day already stabilized at zero. Here's the part nobody talks about: the ten or fourteen days before ceremony can be genuinely hard. If you've been medicated for ADHD since your twenties, coming off means the brain fog, the impulsivity, the missed appointments, and the emotional volatility all come back — right when you're supposed to be preparing calmly for one of the more intense experiences of your life. A few things that help: Some people describe the washout as its own preparatory phase — a stripping-back of the pharmacological scaffolding so the medicine has room to work. That framing helps. Others just find it miserable. Both are valid. People do this. They do it more often than facilitators would like. The logic goes: “I'll just skip a few days, say I'm clean, and get through the ceremony.” Please don't. The reason isn't moral — it's mechanical. If something goes wrong cardiac-wise mid-ceremony, the people around you are making decisions based on the information you gave them. If they think you've been off amphetamines for two weeks and you've actually been off for two days, they will misread the situation. Iboga ceremonies, especially flood doses, run for many hours. There is time for a lot to happen. Give the people who are watching over you the true picture. The same applies in the other direction: if you tried to taper and had to take a dose three days ago because you couldn't function at work, tell your facilitator. They may reschedule. That's a much better outcome than a ceremony that has to be aborted, or worse. Sometimes the honest answer is that this isn't the right month. Signs it might be worth pushing your ceremony date back: Iboga is patient. The retreats are patient. Any facilitator worth sitting with will happily move your date if the medical picture calls for it. The ones who won't — who lean on you to show up regardless — are telling you something important about how they'll handle you in ceremony. Worth naming: many people come to iboga precisely because they want out of a long relationship with stimulant medication. That's a legitimate reason and one iboga has a real track record with — the ibogaine literature on opioid interruption is the famous piece, but its effect on stimulant dependence patterns is also studied and often striking. If part of your reason for sitting with the medicine is to close a chapter with pharmaceutical stimulants, tell your facilitator that too. It changes how they'll frame integration afterward, and what aftercare they'll suggest. Coming off ADHD medication cleanly, whether for a single ceremony or for good, is a real project — not a checkbox. Give it the time and the honesty it deserves. If you're weighing this decision and want to see how different iboga and ibogaine programs handle screening, tapering, and cardiac clearance, curated iboga retreats can be browsed on our marketplace here. Read their intake process carefully — the questions they ask you before you arrive tell you almost everything you need to know about what happens once you do.
Can a Psychedelic Antidepressant Work Without the Trip? Inside the EB-003 Question
Here's a question that keeps showing up in the psychedelic research world, and honestly, it's one of the most interesting ones nobody has a clean answer to yet: do you actually need the trip? Do you need the visions, the ego dissolution, the eight-hour journey through your own psyche to get the antidepressant benefits people report from psilocybin, ayahuasca, and their chemical cousins? Or is the trip a side effect — powerful, meaningful, sure, but not the actual mechanism doing the work? A small biotech in Cambridge, Massachusetts called Enveric Biosciences just added another piece of evidence to one side of that debate. On August 5, 2026, the company (it trades on NASDAQ as ENVB) released new preclinical data on its lead compound, EB-003, that it says strengthens the case for a psychedelic-derived medicine that doesn't get you high. Whether that's a good thing depends on who you ask — and we'll get to that. But first, let's talk about what they actually found. The company tested EB-003 using something called a Promega GloSensor cAMP assay. Skip the jargon for a second — what it really is, is a live-cell test built to pick up on very subtle signaling at what's called the Gi-coupled receptor pathway. That specific pathway has been notoriously tricky to measure with any real precision, which is part of why this whole area has been so slow to develop. Enveric ran EB-003 through the assay next to reference compounds. Some of those references are known hallucinogens. Others are known non-hallucinogens. Think of it as a yardstick — you're checking where your unknown compound falls on a spectrum where the endpoints are already labeled. EB-003 landed in the same neighborhood as the non-hallucinogenic comparators. Not on the tripping side of the fence. Why does this matter more than a typical preclinical readout? Because of a paper published earlier this year in Nature by Xu and colleagues. That research tied hallucinogenic effects specifically to Gi-mediated signaling downstream of the 5-HT2A serotonin receptor. In plain English: the more a compound cranks up that particular pathway, the more likely it seems to make you hallucinate. If that finding holds up under wider scrutiny, drug developers finally have something they've been missing — a preclinical signal that might predict whether a compound will be a trip drug before it ever touches a human volunteer. This isn't Enveric's first attempt at making its case. Back in February, the company published data from its own BRET assays — a different lab technique entirely — showing that EB-003 activates two other signaling pathways at the same 5-HT2A receptor. Those pathways are called Gq and β-arrestin, and both have been linked in peer-reviewed research to antidepressant and anti-anxiety effects. The interesting wrinkle: EB-003 showed a slight preference for β-arrestin over what serotonin itself does. That's the kind of quirky signaling profile drug developers get excited about. Line the two studies up and the story gets clearer. EB-003 seems to activate the pathways associated with therapeutic benefit while staying relatively quiet on the pathway increasingly tied to hallucinations. Two different assay methods. Two different points in time. Both pointing in the same direction. That consistency is probably the actual headline — more than either data set standing alone. The compound itself is designed to hit both 5-HT2A and 5-HT1B receptors, and Enveric describes it as the first candidate built specifically to engage both simultaneously. The goal they're chasing is a fast-acting, durable antidepressant that could be handed out in a normal outpatient setting. No sitter. No dark eyeshades. No clinic room booked for the day. Take it, go home, get on with your life. Here's the part that gets less airtime than the receptor biology but is arguably just as important: the FDA has recently issued final guidance addressing the specific headaches of developing hallucinogenic therapies. And there are a lot of headaches. One of the biggest is what's called functional unblinding. In a normal drug trial, neither the patient nor the person rating the outcomes is supposed to know who got the real drug and who got placebo. That's what makes results trustworthy. But with a psychedelic, everybody knows. If you took two grams of psilocybin, you know. Your rater knows. The janitor probably knows. That kills the scientific rigor of the trial, and regulators are aware of it. On top of that, hallucinogenic therapies require: Enveric's bet is that if EB-003's non-hallucinogenic profile holds up in humans, they can sidestep most of that complexity. Conventional blinded trials. Simpler dosing. An outpatient prescription pad instead of a clinic build-out. That's a much easier commercial path than what companies developing psilocybin therapies are staring down. Here's where I want to push back a little, or at least raise the question that anyone in this space eventually bumps into. If you talk to people who've genuinely healed from depression or trauma through psychedelic-assisted therapy — the kind of healing that seems to stick, not just take the edge off for a few weeks — most of them will tell you the experience itself mattered. The insight, the emotional release, the sense of being shown something about themselves. That's not a side effect to them. That's the treatment. So there's a real philosophical question underneath the biochemistry: are we developing a genuinely psychedelic medicine that happens to skip the trip, or are we developing a new class of conventional antidepressant that happens to be derived from psychedelic research? Those are pretty different things. Neither is bad. But they're different, and the marketing tends to blur that line. None of which is a knock on Enveric's science. Two independent assay platforms pointing the same direction is a meaningfully stronger position than one alone. And for a huge number of people — people who can't take a day off work, people with a history of psychosis in the family, people who simply don't want a psychedelic experience — a non-hallucinogenic option built on this receptor science could be genuinely useful. The next real test comes when EB-003 moves into humans. That's when Enveric will find out whether its receptor-level biology actually translates into the outpatient antidepressant it's designed to be. Assays are elegant. Live people are messier. It's entirely possible EB-003 works exactly as advertised. It's also possible something shows up in Phase 1 that nobody saw coming. That's the nature of drug development. For anyone tracking the broader psychedelic-medicine story, this is worth watching. Not because EB-003 is going to replace ayahuasca ceremonies or psilocybin retreats — it isn't, and it doesn't try to — but because the field is quietly splitting into two branches. One branch is refining the classical psychedelic experience for clinical use. The other is trying to extract the therapeutic mechanism and leave the experience behind. Both branches will probably produce medicines that help real people. They just won't help the same people, or in the same way. If your interest in psychedelics is driven by the experiential side — the ceremony, the insight, the deep work that classical plant medicines are known for — the traditional retreat path is still where that lives, and a range of ayahuasca and plant-medicine retreats can be explored on our marketplace here. The lab compounds are chasing something different, and it'll be a few years yet before we know how well they deliver on the promise.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
